NCT06769659View on ClinicalTrials.gov

A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 11, 2025

Primary Completion Date

March 30, 2026

Study Completion Date

May 30, 2026

Conditions
Epilepsy, GeneralizedEpilepsy, Absence
Interventions
DRUG

NPT 2042

NPT 2042 is a new drug being developed as an anti-seizure treatment

OTHER

Placebo

Placebo Comparator

Trial Locations (1)

77205

RECRUITING

Clinical Trials, Inc. (CTI), Little Rock

Sponsors
All Listed Sponsors
lead

NeuroPro Therapeutics, Inc.

INDUSTRY

NCT06769659 - A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures | Biotech Hunter | Biotech Hunter